Teva Pharmaceutical Industries Limited / Fundamentals
Income statement
- Net revenue
€14.18B - Cost of goods sold
€7.15B - Gross profit
€7.03B - SG&A expenses
€3.20B - R&D expenses
€834.19M - EBITDA
€1.61B - D&A
€872.57M - EBIT
€762.54M - Interest expenses
€800.92M - EBT
-€63.12M - Tax expenses
€79.32M - Net income
-€134.77M
Cash flow statement
- Net deferred tax
-€174.00M - Non-cash items
€1.33B - Changes in working capital
-€822.24M - Operating cash flow
€1.19B - Capex
€426.48M - Other investing cash flow
€1.14B - Net investing cash flow
€773.63M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
-€1.75B - Other financing cash flow
-€310.47M - Net financing cash flow
-€2.06B - Foreign exchange effects
€16.21M - Net change in cash
-€82.74M - Cash at end of period
€1.84B - Free cash flow
€1.61B
Balance sheet
- Cash and cash equivalents
€1.84B - Cash and short-term investments
€1.84B - Total receivables
€3.04B - Inventory
€2.98B - Other current assets
€2.90B - Total current assets
€10.76B - Property, plant & equipment
€4.41B - Goodwill
€13.60B - Intangible assets
€3.53B - Long-term investments
€0.00 - Other non-current assets
€400.89M - Total non-current assets
€23.46B - Total assets
€34.23B - Accounts payable
€2.13B - Short-term debt
€395.77M - Other current liabilities
€7.59B - Total current liabilities
€10.12B - Long-term debt
€14.55B - Deferred tax liabilities
€375.30M - Other non-current liabilities
€3.36B - Total non-current liabilities
€18.28B - Total liabilities
€28.40B - Common stock
€49.47M - Retained earnings
-€12.52B - Other equity
-€2.07B - Total equity
€5.83B - Total liabilities and shareholders' equity
€34.23B
Company information
- Market capitalization
€16.39B - Employees
37K - Enterprise Value
€34.73B
Company ratios
- Gross margin
-
49.6% Better than peer group: 42.0% - EBITDA margin
-
11.4% Worse than peer group: 21.1% - EBIT margin
-
5.4% Worse than peer group: 11.9% - EBT margin
-
-0.4% Worse than peer group: 6.0% - Net margin
-
-1.0% Even with peer group: 0.7% - ROE
-
-2.3% Much worse than peer group: 18.5% - ROA
-
-0.4% Even with peer group: 1.4% - Asset turnover
-
41.4% Worse than peer group: 53.3% - FCF margin
-
5.4% Even with peer group: 5.7% - FCF yield
4.6% - Efficiency ratio
88.6% - Net sales per employee
-
€383.30K - Net income per employee
-
-€3.64K